FDA OKs Novo Nordisk Fast-Acting, Mealtime Insulin

Oct 02, 2017

Novo Nordisk says the U.S. FDA approved Fiasp (insulin aspart injection) 100 Units/mL, a fast-acting mealtime insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes. Fiasp can be dosed at the beginning of a meal or within 20 minutes after starting a meal.

Fiasp is a new formulation of NovoLog, in which the addition of niacinamide (vitamin B3) helps to increase the speed of the initial insulin absorption, resulting in an onset of appearance in the blood in approximately 2.5 minutes. Fiasp will be available in a pre-filled delivery device FlexTouch pen and a 10 mL vial.

Many adults with type 1 and type 2 diabetes struggle with blood sugar control after meals. The result of this has led to many people with diabetes not achieving their target A1C.

Fiasp will launch at the same list price as NovoLog and will be offered with a Savings Card program for eligible patients with commercial insurance to reduce co-pays. Fiasp will also be available to eligible patients through the Novo Nordisk Patient Assistance Program.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments